TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06738303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel and carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PSMA-617
Description: Given IV
Study: NCT04836130

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient specific guide
Description: patient specific guide reduction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional technique
Description: conventional anatomical reduction
Study: NCT04753177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribocyclib, fulvestrant, triptorelin
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribocyclib, fulvestrant, triptorelin
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, cyclophosphamide, paclitaxel
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, paclitaxel
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
Study: NCT06736652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parabolic flight
Description: Preflight each individual was exposed to the 3 Other Interventions and monitored for changes in behavioral performance and neurophysiological responses. In-flight the same monitoring was conducted during partial-gravity (0.25, 0.5. 0.75g) and microgravity (\~0g).
Study: NCT05922085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: performed within 3 hours prior to extubation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasofibroscopie
Description: performed within 24 to 36 hours after extubation
Study: NCT06199999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Block
Description: General anesthesia with Erector Spinae Plane Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration with local anesthetic
Description: General anesthesia with local infiltration of local anesthetic:
Study: NCT06313528

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06568939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion
Study: NCT06562140

Intervention type: OTHER
Intervention: No intervention - cross-sectional observational study
Description: No intervention - cross-sectional observational study
Study: NCT05939284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Cetrorelix
Description: Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral insertion of dydrogeserone
Description: Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
Study: NCT05931770

Intervention type: PROCEDURE
Intervention: Selection of parent(mother or father) according to children preference
Description: The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference

Intervention type: PROCEDURE
Intervention: Parent (mother or father) selection according to parents' preference
Description: Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
Study: NCT06197607

Intervention type: OTHER
Group type: OTHER
Intervention: theraputty hand exercises
Description: Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: theraputty hand exercises
Description: Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sensory stimulation
Description: Sensory Stimulations (30 min) will be given following forms; All and single joint shaking, Multivariate sensory stimulations, Skin stretch in the muscular region, Fast stretch of the upper limb joints in different directions of motor action, brushing on the large muscles of arm and forearm, brushing on the fingers, Circular massage of the thenar and hypothenar area and pressing the tip of fingers.
Study: NCT06315491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
Study: NCT06477263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurocytotron
Description: Neuronal regeneration treatment
Study: NCT04849052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASTERY
Description: In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Control
Description: Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
Study: NCT06569550

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Repetitive Transcranial Magnetic Stimulation
Description: Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The active side is an actively cooled figure-of-eight coil with an outer diameter of 65mm.~Intensity is 80% of resting motor threshold. It is kept the same across all 5 sessions.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France ).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The sham side does not deliver a magnetic pulse to the participant.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France ).
Study: NCT05838625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Therapeutic
Description: A prescription digital therapeutic in the form of a smartphone app.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Therapeutic
Description: A prescription digital therapeutic in the form of a smartphone app.
Study: NCT05664074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Description: Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ketorolac
Description: Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
Study: NCT06407778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Strength Training
Description: * High-intensity workouts to strengthen the quadriceps and enhance knee function;~* Knee flexion and extension 10 lbs.~* 10RM of hip flexion and extension~* 10RM hip adduction and abduction~* Standing with feet aligned for one minute\*2, standing on one leg's forefoot and the other leg's heel for two minutes\*2, standing on one foot for three seconds\*15, and walking ten meters in a straight line for four minutes~* 4-week program; 3 days/week; Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technique
Description: The Muscle Energy Technique (MET) to strengthen and flex your quadriceps and hamstrings.~* After maintaining an isometric contraction for ten seconds, a little stretch was maintained for thirty seconds.~* Four contractions every treatment, separated by three seconds of rest. Standing with feet parallel for one minute\*2, standing on one leg's forefoot and the other leg's heel for two seconds\*2, standing on the forefoot for three seconds\*15~* Move in a 10 m by 4 straight line.~* 4-week program; 3 days/week Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising
Study: NCT05416892

Intervention type: OTHER
Intervention: Pharmaclass® software
Description: Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
Study: NCT06365359

Intervention type: OTHER
Intervention: Blood sample for analysis of plasma of organochlorine pesticides concentration
Description: A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).

Intervention type: OTHER
Intervention: Blood sample for cell collection
Description: A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM.~This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells).
Study: NCT05618587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill
Study: NCT06532799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT06459518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen Therapy along with conventional therapy
Description: Bowen Technique Group Assignment: Participants will be assigned to undergo targeted Bowen Technique therapy sessions.~Session Details: The therapy sessions will include:~* Gentle, rolling-type maneuvers~* Specific placements of fingers and thumbs~* Focus on muscles, tendons, and ligaments associated with neck pain Therapeutic Pauses: There will be intentional pauses between sets of moves to allow the body time to respond to the therapeutic stimulation.~Conventional Therapy: Hot pack, TENS, Passive Stretching 2 times a week for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technique with Conventional Therapy
Description: MET Session Structure: Participants will engage in Muscle Energy Technique (MET) sessions that focus on:~* Isometric muscle contractions, where muscles are contracted without changing length.~* Therapist-guided, controlled contractions against specific resistance.~* Relaxation Periods: Each contraction session will be followed by a period of relaxation to allow muscles to recover and respond to the therapy.~conventional therapy: Hot pack, TENS, Passive Stretching 2times a week for 4 weeks.
Study: NCT05006430

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain fecal material.
Study: NCT05126030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topaz TTVR System
Description: Transcatheter tricuspid heart valve replacement
Study: NCT06215378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antagonization of heparin with protamine sulfate
Description: A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
Study: NCT05789212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Trial ABCCBA
Description: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A-mindfulness, B-yoga, and C-guided walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Trial CBAABC
Description: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A-mindfulness, B-yoga, and C-guided walking.
Study: NCT05833425

Intervention type: DEVICE
Intervention: Respiratory Pressure Meter (MicroRPM)
Description: Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.

Intervention type: DEVICE
Intervention: Respiratory Pressure Meter (MicroRPM)
Description: Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.
Study: NCT05269901

Intervention type: GENETIC
Intervention: SLC7A11, GPX4, P53
Description: Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups

Intervention type: GENETIC
Intervention: SLC7A11, GPX4, P53
Description: Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups
Study: NCT04516681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: 1.5g/kg/day, D1-3, every 2 weeks
Study: NCT04850755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor in combination with nivolumab and ipilimumab
Description: Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
Study: NCT04516681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX Protocol
Description: Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX Protocol
Description: Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/Kg intravenously every 3 weeks
Study: NCT06737432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RKP Monitoring Software
Description: Use of RKP alerting and monitoring software.
Study: NCT06738537

Intervention type: OTHER
Intervention: Focus Groups/Quantitative Survey for Patients
Description: 5 quantitative focus groups will be conducted with 5-10 patients each to elicit the range of outcomes patients consider important when selecting treatment options. 100 quantitative surveys to characterize how patients with severe MR prioritize outcomes when making treatment decisions.

Intervention type: OTHER
Intervention: Focus Group/Quantitative Survey for HCPs
Description: 5 quantitative focus groups will be conducted with 5-10 providers to elicit the range of outcomes providers consider important when recommending treatment options to patients. 100 quantitative surveys to characterize how providers prioritize outcomes for patients with severe MR when making treatment recommendations.

Intervention type: OTHER
Intervention: Qualitative Focus Group
Description: Qualitative focus groups will be conducted to determine barriers and facilitators to implementing shared decision making in multidisciplinary mitral valve heart team clinics.
Study: NCT06738615

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure volume loop evaluation
Description: During the left heart catheterization there are catheters which are introduced into the left ventricle to measure left ventricular pressures and into the coronary arteries to assess their patency. This study will require the placement of an additional specialized catheter made into the left ventricle to measure the change of pressure and volume during the cardiac cycle. This will allow the measurement of heart muscle stiffness.

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiovascular magnetic resonance imaging
Description: Patients will undergo standard cardiovascular magnetic resonance imaging of their heart to measure their heart size, heart function, and severity of mitral regurgitation. In addition, contrast will be administered and heart tissue will be assessed for scarring or fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: A CPET will be performed to objectively measure a patient ability to perform exercise.

Intervention type: DIAGNOSTIC_TEST
Intervention: Kansas City Cardiomyopathy Questionairre
Description: This is a short questionnaire which objectively quantifies symptom burden
Study: NCT06739915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TUTT-PT Intervention
Description: All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.
Study: NCT06737198

Intervention type: OTHER
Intervention: without interventios.
Description: without interventios.